17.2 Syncope Evaluation & Status Epilepticus

Differential Diagnosis of Transient Loss of Consciousness (TLOC)

Transient Loss of Consciousness (TLOC) is defined as a state of real or apparent loss of consciousness characterized by amnesia for the period of the event, abnormal motor control, loss of responsiveness, and brief duration. Clinical differentiation among Syncope, Generalized Epileptic Seizures, and Psychogenic Non-Epileptic Seizures (PNES) is paramount, as misdiagnosis leads to unnecessary anti-seizure drug toxicity, driving restrictions, or missed fatal cardiac arrhythmias.

Comprehensive Clinical Discriminators of TLOC

Clinical Discriminator Pearls

• Lateral Tongue Biting: Spasm of the lateral pterygoid and masseter muscles during generalized epileptic seizure forces the lateral margin of the tongue between the molars, producing deep lateral lacerations. Conversely, tongue injuries in syncope are secondary to blunt trauma against the incisors during a fall, producing abrasions confined to the tip of the tongue.
• Convulsive Syncope: When cerebral perfusion ceases for >5 to 10 seconds, brief cortical and subcortical ischemic release occurs, producing non-rhythmic, asynchronous myoclonic jerking. Clinicians frequently misdiagnose convulsive syncope as epilepsy; the absence of lateral tongue biting, lack of a prolonged postictal state, and immediate lucidity confirm syncope.
• Urinary Incontinence: Can occur in both syncope and epileptic seizures due to sudden loss of central autonomic inhibition over the bladder detrusor muscle. It possesses zero discriminatory value.

---

Clinical Prediction Tools for Syncope: San Francisco Rule & Canadian Score

Syncope accounts for 1% to 3% of all emergency department visits. The clinical mandate is to distinguish benign reflex syncope from life-threatening cardiovascular etiologies carrying high 30-day risks of sudden cardiac death.

The San Francisco Syncope Rule (SFSR)

The SFSR was developed to identify patients at high risk for serious 30-day outcomes (death, acute myocardial infarction, life-threatening arrhythmia, pulmonary embolism, stroke, subarachnoid hemorrhage, or severe hemorrhage requiring transfusion ≥ 2 units). Patients meeting ANY ONE OF THE 5 "CHESS" CRITERIA are classified as HIGH RISK and require admission with continuous telemetry monitoring:

                  THE SAN FRANCISCO SYNCOPE RULE: "CHESS"
                  
    ┌───┬────────────────────────────────────────────────────────────────────┐
    │ C │ History of CONGESTIVE HEART FAILURE                                │
    │   │ • Documented ischemic or non-ischemic cardiomyopathy               │
    │   │ • Clinical signs of active decompensation (rales, JVD, S3)         │
    ├───┼────────────────────────────────────────────────────────────────────┤
    │ H │ HEMATOCRIT <30% (or Hemoglobin <10 g/dL)                           │
    │   │ • Suggests occult gastrointestinal bleeding or major hemorrhage    │
    ├───┼────────────────────────────────────────────────────────────────────┤
    │ E │ ABNORMAL ECG                                                       │
    │   │ • Any non-sinus rhythm (atrial fibrillation, flutter, VT, SVT)     │
    │   │ • Conduction delay: QRS >120 ms, LBBB, bifascicular block          │
    │   │ • Pathological Q waves, ischemic ST-segment/T-wave changes         │
    │   │ • Long QTc interval (>450 ms in men, >460 ms in women)             │
    │   │ • Brugada pattern, pre-excitation (short PR, delta wave)           │
    ├───┼────────────────────────────────────────────────────────────────────┤
    │ S │ SHORTNESS OF BREATH                                                │
    │   │ • Dyspnea pointing toward pulmonary embolism, acute MI, or heart   │
    │   │   failure exacerbation                                             │
    ├───┼────────────────────────────────────────────────────────────────────┤
    │ S │ SYSTOLIC BLOOD PRESSURE <90 mm Hg                                  │
    │   │ • Triage hypotension reflecting cardiogenic, hypovolemic, or       │
    │   │   distributive shock                                               │
    └───┴────────────────────────────────────────────────────────────────────┘

The Canadian Syncope Risk Score (CSRS)

The CSRS is an internationally validated, 9-variable clinical decision model that stratifies 30-day serious adverse cardiovascular outcomes from Very Low (-3 to -2 points, 0.4% risk) to Very High (≥ 6 points, >80% risk):

• Clinical evaluation: Predisposition to vasovagal syncope (-1), history of heart disease (+1), SBP <90 or >180 mm Hg (+2).
• Investigations: Elevated cardiac troponin I/T (+2), abnormal ECG (+1).
• ED impression: Vasovagal syncope (-2), cardiac syncope (+2).

---

Etiological Spectrum & Risk Stratification of Syncope

1. Cardiac Syncope (High-Risk: Predicts 30-Day Sudden Death)

Cardiac syncope results from an acute reduction in cardiac output due to either electrical arrhythmias or mechanical/structural obstruction. Untreated 1-year mortality approaches 20% to 30%.

A. Arrhythmic Etiologies

• Ventricular Tachycardia (VT): Most common cause of cardiac syncope in patients with prior myocardial infarction, ischemic cardiomyopathy, or depressed left ventricular ejection fraction (LVEF <35%).
• High-Grade Atrioventricular (AV) Conduction Blocks: Mobitz type II second-degree AV block and third-degree complete AV block (producing abrupt ventricular standstill or profound bradycardia; Stokes-Adams attacks).
• Sinus Node Dysfunction (Sick Sinus Syndrome): Severe sinus bradycardia, sinoatrial exit block, or prolonged sinus pauses >3 seconds (especially during tachy-brady syndrome upon termination of rapid atrial fibrillation).
• Inherited Cardiac Channelopathies:
  • Brugada Syndrome: Autosomal dominant mutation in cardiac sodium channels (SCN5A). Characteristic ECG: coved ST-segment elevation ≥ 2 mm followed by a negative T wave across leads V1–V2 (Type 1 Brugada pattern). Predisposes to polymorphic VT and ventricular fibrillation, particularly during febrile illnesses or sleep. Requires implantable cardioverter-defibrillator (ICD).
  • Congenital Long QT Syndrome (LQTS): Genetic mutations in potassium or sodium channels prolonging ventricular repolarization (QTc >460 ms in males, >480 ms in females; >500 ms carries extreme risk of Torsades de Pointes). Subtypes: LQT1 (triggered by exercise/swimming), LQT2 (triggered by loud auditory stimuli/alarm clocks), LQT3 (triggered by sleep/rest).
  • Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Fibrofatty replacement of RV myocardium. ECG features: T-wave inversions in V1–V3 and an epsilon wave (notched deflection at the terminal end of the QRS complex).
  • Wolff-Parkinson-White (WPW) Syndrome: Short PR interval (<120 ms), widened QRS with a slur (delta wave); syncope reflects rapid pre-excited atrial fibrillation traversing the accessory pathway.

B. Structural & Mechanical Obstructive Etiologies

• Severe Aortic Stenosis: Classic triad of exertional syncope, angina, and dyspnea. In severe AS (aortic valve area <1.0 cm², mean gradient >40 mm Hg), exercise-induced skeletal muscle vasodilation cannot be matched by an increase in cardiac output across the fixed, calcified orifice, precipitating profound cerebral hypoperfusion. Physical findings: Harsh, crescendo-decrescendo late-peaking systolic ejection murmur radiating to the carotids with pulsus parvus et tardus (weak, delayed carotid upstroke).
• Hypertrophic Cardiomyopathy (HCM): Asymmetric septal hypertrophy causing dynamic left ventricular outflow tract (LVOT) obstruction and systolic anterior motion (SAM) of the anterior mitral valve leaflet. Physical findings: Harsh systolic ejection murmur at the left lower sternal border that intensifies with Valsalva strain or standing (decreased preload worsens obstruction) and softens with squatting (increased preload opens outflow tract).
• Massive Pulmonary Embolism: Physical saddle obstruction of the main pulmonary artery trunk causing acute RV collapse and left ventricular underfilling.
• Acute Aortic Dissection (Type A): Retrograde extension causing acute hemopericardium and cardiac tamponade.
• Atrial Myxoma: Pedunculated intracavitary benign cardiac tumor (most commonly left atrium) that intermittently prolapses into and obstructs the mitral valve orifice when upright.

Red Flags Demanding Immediate Admission for Cardiac Syncope

1. Syncope occurring during physical exertion or active exercise (strongly correlates with severe AS, HCM, or anomalous coronary arteries).
2. Syncope occurring in the supine position or while lying flat (rules out orthostatic and vasovagal etiologies; highly specific for an arrhythmia).
3. Absence of any prodromal warning symptoms (sudden unheralded drop attack).
4. Syncope preceded immediately by rapid, fluttering palpitations or angina.
5. Family history of unexplained sudden cardiac death, drowning, or fatal single-vehicle accidents at age <40 years.
6. Known severe underlying structural heart disease (prior MI, severe congestive heart failure, LVEF <35%).

---

2. Orthostatic Syncope

Occurs when gravitational pooling of blood within the venous capacitance vessels of the lower extremities and splanchnic circulation upon standing impairs venous return, resulting in a precipitous drop in stroke volume and arterial pressure.

• Diagnostic Criteria for Orthostatic Hypotension: A sustained reduction in systolic blood pressure of ≥ 20 mm Hg OR a reduction in diastolic blood pressure of ≥ 10 mm Hg within 3 minutes of standing from a supine position (or during head-up tilt testing).
• Clinical Categories:
  • Intravascular Volume Depletion: Dehydration, persistent vomiting, diarrhea, acute hemorrhage, excessive diaphoresis, or over-diuresis.
  • Medication-Induced (Most Common): Antihypertensives (diuretics, ACE inhibitors, beta-blockers), alpha-1 adrenergic antagonists (tamsulosin, doxazosin, prazosin), vasodilators (nitrates, hydralazine), PDE-5 inhibitors (sildenafil), tricyclic antidepressants, and phenothiazines.
  • Neurogenic Orthostatic Hypotension (Autonomic Failure): Failure of baroreceptor-mediated vasoconstriction. Observed in primary neurodegenerative disorders (Parkinson's disease, Multiple System Atrophy [Shy-Drager syndrome], Pure Autonomic Failure) and secondary autonomic neuropathies (Diabetic autonomic neuropathy, amyloidosis, Guillain-Barré syndrome). Key sign: Absence of compensatory reflex tachycardia upon standing (heart rate increases by <10 bpm despite marked hypotension).

---

3. Neurally-Mediated (Reflex) Syncope (Benign)

Reflex syncope is characterized by an inappropriate, paradoxical neurocardiovascular reflex causing systemic vasodilation (vasodepressor response) and/or bradycardia (cardioinhibitory response).

• Vasovagal Syncope (Common Neurocardiogenic Faint):
  • Triggers: Intense emotional distress, fear, severe pain, sight of blood, medical instrumentation (venipuncture), or prolonged motionless standing in crowded, overheated rooms.
  • Pathophysiology: Sympathetic surge triggers vigorous ventricular contraction against an underfilled chamber, activating ventricular mechanoreceptors (Bezold-Jarisch reflex). This paradoxically triggers massive vagal efferent discharge (causing sinus bradycardia or sinus arrest) and sympathetic withdrawal (causing peripheral arteriolar and venous dilation).
  • Classic Prodrome: Sweating (diaphoresis), warmth, pallor, yawning, nausea, abdominal discomfort, visual blurring, and lightheadedness lasting seconds to minutes before collapse.
• Situational Syncope:
  • Micturition Syncope: Occurs during or immediately after nocturnal urination in men standing to void; rapid relief of bladder distension triggers a vagal surge, compounded by nighttime orthostasis and warm bed-to-bathroom vasodilation.
  • Defecation Syncope: Triggered by prolonged Valsalva straining during difficult bowel movements.
  • Cough (Tussive) Syncope: Paroxysms of coughing markedly increase intrathoracic pressure, impeding venous return to the right heart.
  • Swallow Syncope: Deglutition triggers vagal esophageal mechanoreceptors.
• Carotid Sinus Hypersensitivity:
  • Exaggerated baroreceptor reflex triggered by mechanical stimulation of the carotid bulb (turning neck, looking upward, shaving, wearing tight collars).
  • Diagnostic Confirmation: Carotid sinus massage performed under continuous ECG monitoring (after auscultating to exclude carotid bruits and history of TIA/stroke). Positive response: ventricular pause ≥ 3 seconds (cardioinhibitory) or a drop in SBP ≥ 50 mm Hg without significant bradycardia (vasodepressor).

---

Status Epilepticus (SE): Operational Definition & Pathophysiology

Status epilepticus is a medical emergency characterized by the failure of endogenous mechanisms responsible for terminating seizures, or the initiation of mechanisms that lead to abnormally prolonged seizure activity.

Operational Guideline Definition (Neurocritical Care Society & AES)

Historical definitions required 30 minutes of continuous seizure activity. Current neurocritical guidelines establish a dual-time-point operational framework based on when emergency pharmacotherapy must begin (t1) and when long-term irreversible neuronal injury starts (t2):

                  STATUS EPILEPTICUS DUAL-TIME-POINT DEFINITION
                  
         t1 = 5 MINUTES                                    t2 = 30 MINUTES
    ───────────┼──────────────────────────────────────────────────┼───────────►
               │                                                  │
               ▼                                                  ▼
    OPERATIONAL THRESHOLD:                             NEURONAL INJURY THRESHOLD:
    • Seizure lasting ≥5 min, OR                       • Irreversible neuronal necrosis
    • ≥2 seizures without complete                       and cell death actively ensue
      recovery of consciousness                        • Alteration of neuronal networks
    • MANDATES IMMEDIATE FIRST-LINE                    • Severe systemic complications
      EMERGENCY PHARMACOTHERAPY                          (acidosis, rhabdomyolysis)

• Time Point 1 (t1 = 5 minutes): A generalized convulsive seizure lasting ≥ 5 minutes rarely terminates spontaneously and requires immediate emergency pharmacotherapy. (For focal status epilepticus with impaired awareness, t1 = 10 minutes).
• Time Point 2 (t2 = 30 minutes): Duration beyond which irreversible neuronal injury, excitotoxic cell death, and permanent network reorganization occur. (For focal status epilepticus, t2 = 60 minutes).

Cellular Pathophysiology & Receptor Trafficking

Within minutes of continuous seizure activity, dramatic receptor trafficking alters neuronal membrane responsiveness:

1. GABA-A Receptor Internalization: Synaptic GABA-A receptors undergo clathrin-mediated endocytosis into intracellular endosomes, reducing the number of functional inhibitory GABA-A receptors on the postsynaptic membrane. Consequently, the brain becomes progressively refractory to benzodiazepines (which require functional GABA-A receptors to exert their inhibitory effect).
2. Glutamate Receptor Mobilization: Concurrently, excitatory NMDA and AMPA glutamate receptors are translocated from intracellular stores to the postsynaptic membrane, upregulating excitatory transmission.
3. Excitotoxicity & Systemic Collapse: Continuous glutamatergic stimulation causes massive intracellular calcium influx, activating proteases, lipases, and apoptotic cascades, destroying hippocampal CA1/CA3 pyramidal neurons and cortical layers. Systemically, unremitting muscle contraction triggers severe lactic acidosis (pH frequently <7.0), hyperthermia (>40°C), rhabdomyolysis, hyperkalemia, acute tubular necrosis, and cardiac arrhythmias.

---

Stepwise Pharmacological Management of Status Epilepticus

Management must proceed rapidly through four sequential, time-delineated phases. Underdosing of first-line benzodiazepines is the single most prevalent mistake in clinical practice and leads directly to treatment failure.

                STATUS EPILEPTICUS STEPWISE PHARMACOTHERAPY
                
    ┌────────────────────────────────────────────────────────────────────────┐
    │ PHASE 1: STABILIZATION & EVALUATION (0 TO 5 MINUTES)                   │
    │ • Airway, Breathing, Circulation; high-flow O2 via non-rebreather      │
    │ • Continuous cardiac telemetry, pulse oximetry, blood pressure         │
    │ • STAT Point-of-Care Capillary Glucose: If <70 mg/dL, give D50W 50 mL  │
    │ • If alcohol use / malnutrition suspected: IV THIAMINE 100–500 mg      │
    │   BEFORE Dextrose                                                      │
    │ • Establish two large-bore peripheral IV lines                         │
    │ • STAT Labs: CBC, CMP, Mg, Phos, Ca, Tox screen, AED levels, ABG/VBG   │
    └───────────────────────────────────┬────────────────────────────────────┘
                                        │ Seizure continues ≥5 minutes
                                        ▼
    ┌────────────────────────────────────────────────────────────────────────┐
    │ PHASE 2: EMERGENT INITIAL THERAPY (5 TO 20 MINUTES)                    │
    │ FIRST-LINE BENZODIAZEPINES (FULL WEIGHT-BASED DOSES):                  │
    │ • IF IV ACCESS AVAILABLE:                                              │
    │   - IV LORAZEPAM: 0.1 mg/kg IV (typical dose 4 mg IV push over 2 min); │
    │     may repeat once after 5–10 min if seizure persists                 │
    │ • IF NO IV ACCESS AVAILABLE (IM IS FASTER THAN IV DELAY - RAMPART):    │
    │   - IM MIDAZOLAM: 10 mg IM single dose (>40 kg) (5 mg IM if 13–40 kg)  │
    │ • ALTERNATIVE IF NO IV/IM:                                             │
    │   - RECTAL DIAZEPAM GEL (Diastat): 0.2 mg/kg per rectum (max 20 mg)    │
    │   - Intranasal Midazolam: 0.2 mg/kg (max 10 mg)                        │
    └───────────────────────────────────┬────────────────────────────────────┘
                                        │ Seizure continues ≥20 minutes
                                        ▼
    ┌────────────────────────────────────────────────────────────────────────┐
    │ PHASE 3: URGENT CONTROL THERAPY (20 TO 40 MINUTES)                     │
    │ SECOND-LINE IV ANTIEPILEPTIC DRUGS (ESETT TRIAL: EQUAL EFFICACY ~50%): │
    │ • IV LEVETIRACETAM (Keppra): 60 mg/kg IV over 10 min (MAX 4500 mg)     │
    │   - Minimal cardiac/hemodynamic side effects; no drug interactions     │
    │ • IV FOSPHENYTOIN (Cerebyx): 20 mg PE/kg IV (MAX 1500 mg PE) @ 150 mg/m│
    │   - Water-soluble prodrug; avoids purple-glove tissue necrosis         │
    │   - Requires continuous ECG monitoring (can cause bradycardia/hypotn)  │
    │ • IV SODIUM VALPROATE: 40 mg/kg IV over 10 min (MAX 3000 mg)           │
    │   - Contraindicated in acute liver disease, pregnancy, urea cycle d/o  │
    └───────────────────────────────────┬────────────────────────────────────┘
                                        │ Seizure continues ≥40 minutes
                                        ▼
    ┌────────────────────────────────────────────────────────────────────────┐
    │ PHASE 4: REFRACTORY STATUS EPILEPTICUS (RSE, >40 MINUTES)              │
    │ ICU ADMISSION, ENDOTRACHEAL INTUBATION & GENERAL ANESTHETIC INFUSION:  │
    │ • Endotracheal intubation with rapid-sequence induction (avoid succin- │
    │   ylcholine if hyperkalemic/rhabdomyolysis; use rocuronium 1.2 mg/kg)  │
    │ • CONTINUOUS VIDEO-EEG MONITORING (MANDATORY): Rule out non-convulsive │
    │   status epilepticus (electromechanical decoupling)                    │
    │ • TITRATABLE ANESTHETIC CONTINUOUS INFUSIONS:                          │
    │   - PROPOFOL: 1–2 mg/kg IV bolus, then 2–10 mg/kg/hour continuous     │
    │     infusion (watch for Propofol Infusion Syndrome [PRIS])             │
    │   - MIDAZOLAM: 0.2 mg/kg IV bolus, then 0.05–2.0 mg/kg/hour infusion   │
    │   - KETAMINE: 1–2 mg/kg IV bolus, then infusion (blocks upregulated    │
    │     NMDA receptors; excellent hemodynamic stability)                   │
    │ • Titrate infusions to electrographic burst suppression (10–15s pause) │
    └────────────────────────────────────────────────────────────────────────┘

Critical Clinical Pearls in Status Management

• The RAMPART Trial: Demonstrated that prehospital intramuscular midazolam (10 mg IM) is non-inferior (and resulted in a higher rate of seizure cessation prior to ED arrival: 73% vs 63%) compared to intravenous lorazepam (4 mg IV). Establishing IV access in a violently seizing patient causes substantial treatment delays; IM midazolam should be administered immediately if an IV line is not already in place.
• The ESETT Trial: Demonstrated that in status epilepticus refractory to benzodiazepines, levetiracetam (60 mg/kg), fosphenytoin (20 mg PE/kg), and valproate sodium (40 mg/kg) had statistically indistinguishable rates of seizure cessation (~47% each) and identical safety profiles. Levetiracetam is often preferred in clinical practice due to rapid infusion time, lack of cardiotoxicity, and zero hepatic cytochrome P450 interactions.
• Non-Convulsive Status Epilepticus (Electromechanical Decoupling): After 30 to 45 minutes of convulsive status epilepticus, overt rhythmic motor jerking frequently diminishes or ceases completely due to neuromuscular exhaustion. However, continuous, damaging electrographic seizure activity persists in the brain (Non-Convulsive Status Epilepticus). Continuous EEG (cEEG) monitoring is mandatory in any patient who does not regain consciousness within 20 minutes of convulsive seizure termination.